跳转至内容
Merck

Y0000458

瑞格列奈

European Pharmacopoeia (EP) Reference Standard

别名:

瑞格列奈, (S)-(+)-2-乙氧基-4- [N- [1-(2-哌啶苯基)-3-甲基-1-丁基] 氨基羰基甲基] 苯甲酸, Novonorm, Prandin

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C27H36N2O4
分子量:
452.59
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

repaglinide

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

SMILES 字串

CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N3CCCCC3)ccc1C(O)=O

InChI

1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1

InChI 密鑰

FAEKWTJYAYMJKF-QHCPKHFHSA-N

基因資訊

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Repaglinide for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

瑞格列奈是一种有效的短效胰岛素促分泌剂,可通过关闭胰岛β细胞质膜中的ATP敏感性钾(KATP)通道发挥作用。 它是一类新的胰岛素促分泌素,其结构上与磺酰脲无关,专为治疗2型糖尿病而开发。

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Christina Jarnert et al.
Diabetes & vascular disease research, 9(4), 287-295 (2012-03-02)
Microcirculatory and endothelial dysfunction are signs of cardiovascular engagement in patients with type 2 diabetes. This study tested whether glucose normalisation may reverse this. Thirty-nine T2DM patients (age 61±7 years, 58% females) with signs of mild diastolic dysfunction were randomised
Deaths in trials should always be reported.
Jeppe Schroll
BMJ (Clinical research ed.), 347, f4219-f4219 (2013-07-06)
Qian Xiang et al.
Pharmacology, 89(1-2), 105-110 (2012-03-09)
The aim of this study was to evaluate the pharmacogenetic variability in the disposition of repaglinide in healthy Chinese subjects. A single dose of 2 mg repaglinide was orally administered to 24 healthy Chinese subjects. The serum concentrations of repaglinide
Severe thrombocytopenia due to repaglinide in a patient with type 2 diabetes.
Hisayuki Katsuyama et al.
Diabetes care, 36(3), e36-e36 (2013-02-23)
Karelle Ménochet et al.
Drug metabolism and disposition: the biological fate of chemicals, 40(9), 1744-1756 (2012-06-06)
Interindividual variability in activity of uptake transporters is evident in vivo, yet limited data exist in vitro, confounding in vitro-in vivo extrapolation. The uptake kinetics of seven organic anion-transporting polypeptide substrates was investigated over a concentration range in plated cryopreserved

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门